43P MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy

Ticiana Leal, David Berz, Igor I. Rybkin, Wade T. Iams, Débora S. Bruno, Collin M. Blakely, Alexander I. Spira, Manish R. Patel, David Waterhouse, Donald Richards, Anthony Pham, Robert M. Jotte, E.B. Garon, David S. Hong, Ronald Shazer, Xiaohong Yan, L. Latven, Kai He